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Human Langerhans cells are immature in melanoma sentinel lymph nodes
The specific function of Langerhans cells (LCs) in the skin
immune system is controversial and a matter of intense debate.1
As epidermal LCs are potential targets for cancer immuno-
therapy, the topic is of primary importance.2 Recently, van de
Ven et al showed that LCs are phenotypically mature,3 but,
surprisingly, functionally defective in melanoma negative senti-
nel lymph nodes (SLNs).3 Complementing that study, we
additionally analyzed LCs in melanoma positive as well as
negative SLNs and, in light of the obtained data, we believe that
LC immunophenotype in melanoma patients deserves addi-
tional, critical discussion.
Building on our previous study showing that LCs are the
most represented DC subset in melanoma SLNs,4 we now
analyzed their immunophenotype and compared it with both
freshly isolated and epidermal explant–migrated LCs as proto-
types of immature and mature LCs, respectively. Melanoma
patients undergoing SLN biopsy were enrolled after informed
written consent and local institutional ethics committee approval.
We investigated 16 melanoma positive SLNs (from 11 patients;
stage III; 4 women, 7 men; mean age 62 years, range 25-84 years;
average Breslow thickness 3.21 mm, range 0.45-10.4 mm; mean
interval from melanoma excision 10 days, range 0-39 days), and
27 melanoma negative SLNs (from 16 patients; stage I/II; 4 women,
12 men; mean age 57 years, range 19-86 years; average Breslow
thickness 2.43 mm, range 0.58-14 mm; mean interval from mela-
noma excision 16 days, range 0-56 days). By means of combina-
tional analysis of percentage of positive cells and mean fluores-
cence intensity, we found that CD83, CD80, CD86, and HLA-DR
expression in LCs from both negative and positive SLNs was lower
than that found in LCs migrated from epidermal explants and,
oddly, similar to that observed in freshly isolated epidermal LCs
(Figure 1). Importantly, while the expression of co-stimulatory
molecules CD80 and CD86 in LCs from negative SLNs was
similar to that reported by van de Ven et al,3 the percentage of
LCs expressing the prototypical DC maturation marker CD83
was considerably lower (16.68  7.73% vs 45-50%; see Figure
3A in van de Ven et al).3 We reason that this remarkable
difference depends on the fact that we immediately performed
cell analysis on SLN biopsy, to avoid DC activation,5 at variance
with van de Ven et al.3 Alternatively, the immature LC immunophe-
notype can be ascribed to the short mean interval from primary
melanoma excision and SLN biopsy we conducted (16 days) in
comparison to van de Ven et al (44 days3), a condition that might
preserve the melanoma-induced suppressive effects on SLNs.
Consistently, the percentage of LCs expressing CD83 in positive
SLNs was significantly lower than that found in negative SLNs
(6.51 2.26% and 16.68 7.73%, respectively), whereas that of
LCs expressing CD80, CD86, and HLA-DR did not differ signifi-
cantly (Figure 1).
The present findings are in line with previous reports showing
phenotypic and functional defects of DCs in cancer patient SLNs,
which harbor a highly immunosuppressive microenvironment.6,7 In
conclusion, LCs in melanoma patients migrate from the skin to
SLNs with an immature phenotype, which is crucial to tolerate
melanoma associated antigens.8 Although the presence of imma-
ture LCs might indicate a steady-state condition,9 the obtained data
strongly suggest a melanoma-related effect.
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Figure 1. Flow cytometry analyses of LCs in SLN
from melanoma patients. SLN single cell suspension
was obtained as described3 with modifications.4 Cells
were collected in PBS, without enzymatic treatments or
culturing, and immediately processed for flow cytometry
analysis. Five-color cell staining was performed after cell
membrane permeabilization with antibodies against Lan-
gerin PE (Immunotech), CD80 FITC and CD86 Pe-Cy5
(BD Pharmingen), CD83 APC and HLA-DR Pe-Cy7
(BioLegend). Cells were analyzed using FACS Canto
with FACSDiva Version 6.0 software (BD Immunocytom-
etry Systems). Isotype-matched Abs were used as nega-
tive controls. Results are expressed as percentages of
double positive cells (left panels) and mean fluorescence
intensity (right panels) among total gated Langerin cells,
from freshly isolated and in vitro-migrated epidermal LCs
(n  5; from normal skin dermatomes of informed pa-
tients undergoing plastic surgery) and negative and
positive SLNs LCs (n  27 and n  16, respectively).
Bars represent mean value and asterisks indicate P value
by 2-side Student t test statistical analysis (*P  .05;
**P  .01; ***P  .001, respectively).
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